Melbourne-based Tryptamine Therapeutics (ASX: TYP) has received highly encouraging results from its recently completed Phase 2a clinical trial conducted in collaboration with the University of Michigan (UOM) .
The company said the results are both significant and clinically meaningful, and were recently presented by UOM researchers at the International Association for the Study of Pain (IASP) 2024 World Congress in the Netherlands,
The trial was designed to evaluate TRP-8802 (oral psilocybin) in conjunction with psychotherapy in patients with fibromyalgia, a condition associated with widespread pain and comorbidities that significantly impact daily living and patient well-being.
Results highlighted that 100% of patients experienced reductions in fibromyalgia pain and sleep disturbance.
“Fibromyalgia is a complex and widespread condition, impacting one million Australians, and imposes a large emotional, physical and economic burden on every sufferer,” CEO, Jason Carroll, said.
“Despite this, fibromyalgia sufferers have very limited success with current treatments, often resort to the use of opioids and many of these have highly limiting and wide-ranging side effects associated with their use.”
“While still early, these results highlight that psychedelic-assisted therapy may achieve an improved patient outcome through treating the cause of fibromyalgia rather than the limited relief to select symptoms provided from the treatment choices presently open to them. Through this trial we have demonstrated that psychedelic-assisted- therapy may offer an improved future for fibromyalgia patients across Australia and globally.”
“Looking ahead, the company will undertake further analysis of these results in partnership with UOM researchers. These findings will be incorporated into planning now underway for an additional trial utilising TRP-8803, Tryp’s innovative and scalable IV-infused psilocin formulation. We look forward to providing further updates on trial planning in due course.”
